DD204494A5 - Verfahren zum schneiden doppelstraengiger dns - Google Patents

Verfahren zum schneiden doppelstraengiger dns Download PDF

Info

Publication number: DD204494A5
Authority: DD; German Democratic Republic
Prior art keywords: plasmid; polypeptide; trp; fragment; gene
Prior art date: 1980-03-24

Application number

DD81243409A

Other languages

German (de)

English (en)

Inventor

Dennis G Kleid

Daniel G Yansura

Herbert L Heiyneker

Giuseppe F Miozzari

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-03-24

Filing date

1981-03-23

Publication date

1983-11-30

1981-03-23 Application filed by Genentech Inc filed Critical Genentech Inc

1983-11-30 Publication of DD204494A5 publication Critical patent/DD204494A5/de

Links

238000000034 method Methods 0.000 title claims abstract description 37
238000005520 cutting process Methods 0.000 claims abstract description 14
238000006243 chemical reaction Methods 0.000 claims abstract description 12
239000002773 nucleotide Substances 0.000 claims abstract description 12
125000003729 nucleotide group Chemical group 0.000 claims abstract description 12
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims abstract description 8
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims abstract description 8
230000000295 complement effect Effects 0.000 claims abstract description 7
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims abstract description 6
229930024421 Adenine Natural products 0.000 claims abstract description 4
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims abstract description 4
229960000643 adenine Drugs 0.000 claims abstract description 4
229940104302 cytosine Drugs 0.000 claims abstract description 4
229940113082 thymine Drugs 0.000 claims abstract description 3
108060002716 Exonuclease Proteins 0.000 claims description 6
230000000694 effects Effects 0.000 claims description 6
102000013165 exonuclease Human genes 0.000 claims description 6
108020004414 DNA Proteins 0.000 abstract 5
102000053602 DNA Human genes 0.000 abstract 4
108020004682 Single-Stranded DNA Proteins 0.000 abstract 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 abstract 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 abstract 1
239000013612 plasmid Substances 0.000 description 130
108090000623 proteins and genes Proteins 0.000 description 122
229920001184 polypeptide Polymers 0.000 description 114
108090000765 processed proteins & peptides Proteins 0.000 description 114
102000004196 processed proteins & peptides Human genes 0.000 description 113
239000012634 fragment Substances 0.000 description 75
125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 66
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 61
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 61
230000014509 gene expression Effects 0.000 description 41
235000018102 proteins Nutrition 0.000 description 34
102000004169 proteins and genes Human genes 0.000 description 34
239000004098 Tetracycline Substances 0.000 description 32
229960002180 tetracycline Drugs 0.000 description 32
229930101283 tetracycline Natural products 0.000 description 32
235000019364 tetracycline Nutrition 0.000 description 32
150000003522 tetracyclines Chemical class 0.000 description 32
239000000047 product Substances 0.000 description 31
150000001413 amino acids Chemical group 0.000 description 27
102000037865 fusion proteins Human genes 0.000 description 27
108020001507 fusion proteins Proteins 0.000 description 27
239000002609 medium Substances 0.000 description 25
241000588724 Escherichia coli Species 0.000 description 24
210000004027 cell Anatomy 0.000 description 22
108010000521 Human Growth Hormone Proteins 0.000 description 20
229960000723 ampicillin Drugs 0.000 description 20
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 20
230000001580 bacterial effect Effects 0.000 description 20
108020004705 Codon Proteins 0.000 description 18
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
101150101441 dus gene Proteins 0.000 description 18
238000012217 deletion Methods 0.000 description 17
230000037430 deletion Effects 0.000 description 17
230000029087 digestion Effects 0.000 description 17
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 17
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 16
101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 15
108010056088 Somatostatin Proteins 0.000 description 15
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 15
101150044170 trpE gene Proteins 0.000 description 15
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
102000002265 Human Growth Hormone Human genes 0.000 description 14
239000000854 Human Growth Hormone Substances 0.000 description 14
102000005157 Somatostatin Human genes 0.000 description 14
229960000553 somatostatin Drugs 0.000 description 14
241000894006 Bacteria Species 0.000 description 12
238000003780 insertion Methods 0.000 description 12
108091008146 restriction endonucleases Proteins 0.000 description 12
238000013519 translation Methods 0.000 description 12
230000037431 insertion Effects 0.000 description 11
230000001413 cellular effect Effects 0.000 description 10
108091033380 Coding strand Proteins 0.000 description 9
102000007501 Thymosin Human genes 0.000 description 9
108010046075 Thymosin Proteins 0.000 description 9
230000004927 fusion Effects 0.000 description 9
239000006228 supernatant Substances 0.000 description 9
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 9
101150100816 trpD gene Proteins 0.000 description 9
101150079930 trpGD gene Proteins 0.000 description 9
101100122010 Methanocella arvoryzae (strain DSM 22066 / NBRC 105507 / MRE50) glmM gene Proteins 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
238000010276 construction Methods 0.000 description 8
239000000203 mixture Substances 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
239000000872 buffer Substances 0.000 description 7
239000013604 expression vector Substances 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
230000008569 process Effects 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
238000005215 recombination Methods 0.000 description 7
101000976075 Homo sapiens Insulin Proteins 0.000 description 6
102000003960 Ligases Human genes 0.000 description 6
108090000364 Ligases Proteins 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
239000013613 expression plasmid Substances 0.000 description 6
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
230000006798 recombination Effects 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
101000658546 Escherichia coli Type I restriction enzyme EcoEI endonuclease subunit Proteins 0.000 description 5
RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 5
230000003115 biocidal effect Effects 0.000 description 5
238000012869 ethanol precipitation Methods 0.000 description 5
230000003287 optical effect Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
230000009466 transformation Effects 0.000 description 5
238000011144 upstream manufacturing Methods 0.000 description 5
239000013598 vector Substances 0.000 description 5
241001646716 Escherichia coli K-12 Species 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 4
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 4
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
238000000605 extraction Methods 0.000 description 4
230000037361 pathway Effects 0.000 description 4
230000007017 scission Effects 0.000 description 4
238000000926 separation method Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
108010076181 Proinsulin Proteins 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
108050004197 Trp repressor Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000009471 action Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
230000000975 bioactive effect Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000012010 growth Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
238000011160 research Methods 0.000 description 3
239000007320 rich medium Substances 0.000 description 3
230000014621 translational initiation Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
WTFXTQVDAKGDEY-UHFFFAOYSA-N (-)-chorismic acid Natural products OC1C=CC(C(O)=O)=CC1OC(=C)C(O)=O WTFXTQVDAKGDEY-UHFFFAOYSA-N 0.000 description 2
OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 2
LXCUAFVVTHZALS-UHFFFAOYSA-N 3-(3-methoxyphenyl)piperidine Chemical compound COC1=CC=CC(C2CNCCC2)=C1 LXCUAFVVTHZALS-UHFFFAOYSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
WTFXTQVDAKGDEY-HTQZYQBOSA-N Chorismic acid Natural products O[C@@H]1C=CC(C(O)=O)=C[C@H]1OC(=C)C(O)=O WTFXTQVDAKGDEY-HTQZYQBOSA-N 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
108090000204 Dipeptidase 1 Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
101100269389 Mus musculus Pgm3 gene Proteins 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
101100046504 Symbiobacterium thermophilum (strain T / IAM 14863) tnaA2 gene Proteins 0.000 description 2
239000008051 TBE buffer Substances 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
102000006635 beta-lactamase Human genes 0.000 description 2
230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
239000005018 casein Substances 0.000 description 2
235000021240 caseins Nutrition 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000002028 premature Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
239000000126 substance Substances 0.000 description 2
-1 uhymine Chemical compound 0.000 description 2
108700026220 vif Genes Proteins 0.000 description 2
NQEQTYPJSIEPHW-MNOVXSKESA-N (1S,2R)-1-C-(indol-3-yl)glycerol 3-phosphate Chemical compound C1=CC=C2C([C@H](O)[C@@H](COP(O)(O)=O)O)=CNC2=C1 NQEQTYPJSIEPHW-MNOVXSKESA-N 0.000 description 1
SXOUIMVOMIGLHO-UHFFFAOYSA-N 3-(1h-indol-2-yl)prop-2-enoic acid Chemical compound C1=CC=C2NC(C=CC(=O)O)=CC2=C1 SXOUIMVOMIGLHO-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
102000008169 Co-Repressor Proteins Human genes 0.000 description 1
108010060434 Co-Repressor Proteins Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
238000012270 DNA recombination Methods 0.000 description 1
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
241000588921 Enterobacteriaceae Species 0.000 description 1
101710204837 Envelope small membrane protein Proteins 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
101710088839 Replication initiation protein Proteins 0.000 description 1
108010034634 Repressor Proteins Proteins 0.000 description 1
102000009661 Repressor Proteins Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
241000607720 Serratia Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
101100370749 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) trpC1 gene Proteins 0.000 description 1
229930003451 Vitamin B1 Natural products 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
235000005550 amino acid supplement Nutrition 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
238000000137 annealing Methods 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000005660 chlorination reaction Methods 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
239000004927 clay Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
235000015114 espresso Nutrition 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
210000003746 feather Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000000465 moulding Methods 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000000361 pesticidal effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000037048 polymerization activity Effects 0.000 description 1
239000011148 porous material Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000011218 seed culture Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
108010068698 spleen exonuclease Proteins 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000037351 starvation Effects 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960003495 thiamine Drugs 0.000 description 1
DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
101150019416 trpA gene Proteins 0.000 description 1
101150081616 trpB gene Proteins 0.000 description 1
101150111232 trpB-1 gene Proteins 0.000 description 1
101150016309 trpC gene Proteins 0.000 description 1
101150059846 trpS gene Proteins 0.000 description 1
101150004782 trpS2 gene Proteins 0.000 description 1
239000012137 tryptone Substances 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000010374 vitamin B1 Nutrition 0.000 description 1
239000011691 vitamin B1 Substances 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Crystallography & Structural Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)

DD81243409A 1980-03-24 1981-03-23 Verfahren zum schneiden doppelstraengiger dns DD204494A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US13329680A	1980-03-24	1980-03-24

Publications (1)

Publication Number	Publication Date
DD204494A5 true DD204494A5 (de)	1983-11-30

Family

ID=22457906

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DD81243409A DD204494A5 (de)	1980-03-24	1981-03-23	Verfahren zum schneiden doppelstraengiger dns
DD81228534A DD159435A5 (de)	1980-03-24	1981-03-23	Verfahren zum herstellen eines polypeptidproduktes durch expression in bakterien eines dafuer codierenden gens
DD81243408A DD203746A5 (de)	1980-03-24	1981-03-23	Verfahren zur herstellung eines expressionsplasmids

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DD81228534A DD159435A5 (de)	1980-03-24	1981-03-23	Verfahren zum herstellen eines polypeptidproduktes durch expression in bakterien eines dafuer codierenden gens
DD81243408A DD203746A5 (de)	1980-03-24	1981-03-23	Verfahren zur herstellung eines expressionsplasmids

Country Status (35)

Country	Link
US (2)	US5888808A (pt)
EP (3)	EP0154133B1 (pt)
JP (3)	JPH0724582B2 (pt)
KR (2)	KR830005351A (pt)
AR (1)	AR248050A1 (pt)
AT (3)	ATE52802T1 (pt)
AU (3)	AU542640B2 (pt)
BG (3)	BG46005A3 (pt)
BR (1)	BR8101712A (pt)
CA (2)	CA1198068A (pt)
CS (3)	CS238645B2 (pt)
DD (3)	DD204494A5 (pt)
DE (5)	DE3153606C2 (pt)
DK (1)	DK173085B1 (pt)
DZ (1)	DZ278A1 (pt)
ES (3)	ES8207220A1 (pt)
FI (3)	FI810876L (pt)
FR (2)	FR2480781B1 (pt)
GB (1)	GB2073203B (pt)
GR (1)	GR74818B (pt)
HU (1)	HU195534B (pt)
IE (3)	IE51893B1 (pt)
IL (3)	IL62460A (pt)
IT (1)	IT1144324B (pt)
MX (1)	MX7689E (pt)
MY (1)	MY8500896A (pt)
NO (3)	NO810986L (pt)
NZ (3)	NZ207660A (pt)
OA (1)	OA06774A (pt)
PH (4)	PH17537A (pt)
PL (2)	PL147727B1 (pt)
PT (1)	PT72716B (pt)
YU (2)	YU45534B (pt)
ZA (1)	ZA811368B (pt)
ZW (1)	ZW5481A1 (pt)

Families Citing this family (366)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1202581A (en) *	1980-03-27	1986-04-01	Saran A. Narang	Adaptor molecules for dna and their application to synthesis of gene-derived products
GR74498B (pt)	1980-04-03	1984-06-28	Biogen Inc
US4874702A (en) *	1980-09-08	1989-10-17	Biogen, Inc.	Vectors and methods for making such vectors and for expressive cloned genes
DK489481A (da) *	1980-11-10	1982-05-11	Searle & Co	Plasmidvektor og frmgangsmaade til fremstilling deraf
US5525484A (en) *	1981-01-16	1996-06-11	Genome Therapeutics Corp.	Recombinant DNA means and method for producing rennin, prorenin and pre-prorennin
BR8205954A (pt) *	1981-10-14	1983-09-13	Unilever Nv	Sequencia de dna,plasmidio recombinante,cultura bacteriana e microorganismos
JPS58110600A (ja) *	1981-12-25	1983-07-01	Kyowa Hakko Kogyo Co Ltd	ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
JPS58141796A (ja) *	1982-02-18	1983-08-23	Kyowa Hakko Kogyo Co Ltd	ペプチドの製造法
DE3382317D1 (de) *	1982-03-15	1991-07-25	Schering Corp	Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
US4499188A (en) *	1982-05-05	1985-02-12	Cetus Corporation	Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US4863855A (en) *	1982-05-14	1989-09-05	The Research Foundation Of State University Of New York	Novel cloning vehicles for polypeptide expression in microbial hosts
EP0108045B1 (en) *	1982-10-25	1988-12-07	Monsanto Company	Reca promoter dependent polypeptide production
IE56509B1 (en) *	1982-11-04	1991-08-28	Univ California	Methods for oncogenic detection
DE3247922A1 (de) *	1982-12-24	1984-06-28	Boehringer Ingelheim International GmbH, 6507 Ingelheim	Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
US5169762A (en) *	1983-03-03	1992-12-08	Genentech, Inc.	Human nerve growth factor by recombinant technology
DK161152C (da)	1983-03-03	1991-11-11	Genentech Inc	Polypeptid med egenskaber som human beta-nervevaekstfaktor og fremgangsmaade til fremstilling deraf, dna-isolat omfattende en sekvens som koder for polypeptidet, replicerbar udtrykkelsesvektor for dna-sekvensen, rekombinant vaertscelle transformeret med vektoren, farmaceutisk praeparat indeholdende polypeptidet og fremg. der omfatter anvendelsen af polypeptidet til fremst. af et farmaceutisk praeparat
US4701416A (en) *	1983-12-09	1987-10-20	Cetus Corporation	Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
US4935370A (en) *	1983-12-23	1990-06-19	Pfizer Inc.	Expression plasmids for improved production of heterologous protein in bacteria
ATE100494T1 (de) *	1984-02-08	1994-02-15	Cetus Oncology Corp	Kontrollsysteme fuer rekombinant-manipulationen.
US5028531A (en) *	1984-03-19	1991-07-02	Fujisawa Pharmaceutical Company, Ltd.	IGF-I fusion proteins; protection of IGF-I from degradation by host cell; and processes for the production thereof
GB8407044D0 (en) *	1984-03-19	1984-04-26	Fujisawa Pharmaceutical Co	Producing human insulin
US4656132A (en) *	1984-03-28	1987-04-07	Cetus Corporation	Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US4894334A (en) *	1984-03-28	1990-01-16	Cetus Corporation	Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US5268278A (en) *	1984-03-30	1993-12-07	Istituto Farmacologico Serono S.P.A.	Genetic expression of somatostatin as hybrid polypeptide
US4789702A (en) *	1984-05-18	1988-12-06	Cetus Corporation	Feline leukemia virus vaccine
US5683688A (en)	1984-05-31	1997-11-04	Genentech, Inc.	Unglycosylated recombinant human lymphotoxin polypeptides and compositions
EP0165613B1 (en) *	1984-06-22	1992-01-15	Hitachi, Ltd.	Process for controlling culture of recombinants
JPS619282A (ja) *	1984-06-22	1986-01-16	Hitachi Ltd	遺伝子組換え菌の培養方法
JPS6158595A (ja) *	1984-08-28	1986-03-25	ジェネックス・コーポレイション	徴生物によるタンパク質規模生産方法
US4738921A (en) *	1984-09-27	1988-04-19	Eli Lilly And Company	Derivative of the tryptophan operon for expression of fused gene products
NZ213759A (en) *	1984-10-19	1989-01-27	Genentech Inc	Lhrh-ctp protein conjugates influencing prolactin fsh and lh release
US5075224A (en) *	1984-10-19	1991-12-24	Genentech, Inc.	Prepro-LHRH C-terminal peptide DNA
FI90990C (fi) *	1984-12-18	1994-04-25	Boehringer Ingelheim Int	Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
EP0211047B1 (en)	1985-01-28	1994-02-02	Xoma Corporation	Arab promoters and method of producing polypeptides, includinn cecropins, by microbiological techniques
IT1234977B (it) *	1985-03-22	1992-06-09	Serono Ist Farm	Espressione in e. coli polipeptidi ibridi contenenti la sequenza del fattore di rilascio dell'ormone della crescita
US4965188A (en) *	1986-08-22	1990-10-23	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
DK171161B1 (da) *	1985-03-28	1996-07-08	Hoffmann La Roche	Fremgangsmåde til påvisning af forekomst eller fravær af mindst én specifik nukleinsyresekvens i en prøve eller til skelnen mellem to forskellige nukleinsyresekvenser i denne prøve
US4683202A (en) *	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
GB8509289D0 (en) *	1985-04-11	1985-05-15	Fujisawa Pharmaceutical Co	Production of somatostatin
DE3526995A1 (de) *	1985-07-27	1987-02-05	Hoechst Ag	Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
EP0213472A1 (en) *	1985-08-12	1987-03-11	Syntex (U.S.A.) Inc.	Method for producing fusion proteins
ES2000859A6 (es) *	1985-08-12	1988-03-16	Syntex Inc	Un metodo para producir un vector de expresion bacteriana para la expresion de proteinas de fusion
JPH0775536B2 (ja) *	1986-03-26	1995-08-16	猛小林	遺伝子組み換え菌を用いた酵素生産装置
DE3642096A1 (de) *	1986-12-10	1988-06-16	Boehringer Ingelheim Int	Pferde-(gamma)-interferon
US6994988B1 (en)	1987-02-12	2006-02-07	Genetech, Inc.	Methods and deoxyribonucleic acid for the preparation of tissue factor protein
JPH01247099A (ja) *	1988-03-30	1989-10-02	Hitachi Ltd	ヒトの上皮細胞増殖因子の遺伝子工学的生産方法
DE68915841T2 (de) *	1988-03-30	1995-02-02	Hitachi Chemical Co Ltd	Verfahren zur Herstellung von Epidermal-Wachstumsfaktor durch genetische Transformation.
JPH01247098A (ja) *	1988-03-30	1989-10-02	Hitachi Ltd	ヒトの上皮細胞増殖因子の遺伝子工学的生産方法
JPH0227993A (ja) *	1988-07-15	1990-01-30	Nippon Shinyaku Co Ltd	ｈＥＧＦの製法
IL92937A0 (en)	1989-01-31	1990-09-17	Us Health	Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
ES2109336T3 (es)	1990-11-26	1998-01-16	Genetics Inst	Expresion de pace en celulas huesped y metodos de utilizacion de la misma.
DE69333127T2 (de)	1992-06-03	2004-05-06	Genentech, Inc., South San Francisco	Varianten des Gewebeplasminogenaktivators mit verbesserter therapeutischer Wirkung
GB9325182D0 (en) *	1993-12-08	1994-02-09	T Cell Sciences Inc	Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US6001604A (en) *	1993-12-29	1999-12-14	Bio-Technology General Corp.	Refolding of proinsulins without addition of reducing agents
US5629167A (en)	1994-04-19	1997-05-13	Biocine S.P.A.	Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US5708142A (en)	1994-05-27	1998-01-13	Genentech, Inc.	Tumor necrosis factor receptor-associated factors
US6455304B1 (en)	1994-07-01	2002-09-24	The Board Of Regents Of The University Of Oklahoma	Hyaluronate synthase gene and uses thereof
US7091008B1 (en)	1994-07-01	2006-08-15	The Board Of Regents Of The University Of Oklahoma	Hyaluronan synthase genes and expression thereof in Bacillus hosts
US6951743B2 (en)	1997-10-31	2005-10-04	University Of Oklahoma Board Of Regents	Hyaluronan synthase genes and expression thereof in bacillus hosts
US6015660A (en) *	1995-01-06	2000-01-18	The Regents Of The University Of California	Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US6077510A (en) *	1995-01-06	2000-06-20	Regents Of The University Of California	Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US6113905A (en) *	1995-01-06	2000-09-05	The Regents Of The University Of California	Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US5795966A (en)	1995-02-22	1998-08-18	Immunex Corp	Antagonists of interleukin-15
JP4435304B2 (ja)	1995-06-29	2010-03-17	イミュネックス・コーポレーション	アポトーシスを誘導するサイトカイン
US7005505B1 (en)	1995-08-25	2006-02-28	Genentech, Inc.	Variants of vascular endothelial cell growth factor
US6020473A (en) *	1995-08-25	2000-02-01	Genentech, Inc.	Nucleic acids encoding variants of vascular endothelial cell growth factor
US6030945A (en) *	1996-01-09	2000-02-29	Genentech, Inc.	Apo-2 ligand
US6998116B1 (en)	1996-01-09	2006-02-14	Genentech, Inc.	Apo-2 ligand
JP2000507829A (ja)	1996-04-01	2000-06-27	ジェネンテックインコーポレーテッド	Ａｐｏ―２ｌｉおよびａｐｏ―３アポトーシスポリペプチド
US6100071A (en)	1996-05-07	2000-08-08	Genentech, Inc.	Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6159462A (en) *	1996-08-16	2000-12-12	Genentech, Inc.	Uses of Wnt polypeptides
US5851984A (en) *	1996-08-16	1998-12-22	Genentech, Inc.	Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en)	1996-09-23	2002-10-08	Genentech, Inc.	Apo-3 polypeptide
US5990281A (en) *	1996-09-30	1999-11-23	Genentech, Inc.	Vertebrate smoothened proteins
US6544523B1 (en)	1996-11-13	2003-04-08	Chiron Corporation	Mutant forms of Fas ligand and uses thereof
US6242213B1 (en)	1996-12-23	2001-06-05	Immunex Corporation	Isolated DNA molecules encoding RANK-L
WO1999027098A2 (en)	1997-11-21	1999-06-03	Genentech, Inc.	A-33 related antigens and their pharmacological uses
ATE488621T1 (de) *	1997-04-04	2010-12-15	Univ Southern California	Galvanisches verfahren zur herstellung einer mehrlagenstruktur
US6448035B1 (en)	1997-04-24	2002-09-10	Immunex Corporation	Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US6384203B1 (en)	1999-05-12	2002-05-07	Immunex Corporation	Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6342369B1 (en)	1997-05-15	2002-01-29	Genentech, Inc.	Apo-2-receptor
US6291643B1 (en)	1997-06-05	2001-09-18	Board Of Reports, The University Of Texas System	Apaf-1 an activator of caspase-3
JP2002508663A (ja)	1997-06-18	2002-03-19	ジェネンテク，インコーポレイテッド	Ａｐｏ−２ＤｃＲ
US6342220B1 (en)	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
ATE505478T1 (de)	1997-08-27	2011-04-15	Novartis Vaccines & Diagnostic	Molekular-mimetika von meningokokkalen b epitopen
US6610838B1 (en)	1997-09-10	2003-08-26	Symbicom Aktiebolag	P13 antigens from Borrelia
ES2306480T3 (es)	1997-09-18	2008-11-01	Genentech, Inc.	Polipeptido dcr3, un homologo de tnfr.
EP1967587A1 (en)	1997-10-10	2008-09-10	Genentech, Inc.	APO-3 Ligand
AU1288399A (en)	1997-10-29	1999-05-17	Genentech Inc.	Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
ES2316173T3 (es)	1997-10-29	2009-04-01	Genentech, Inc.	Genes inducibles por wnt-1.
AU762036B2 (en)	1997-10-31	2003-06-19	Board Of Regents Of The University Of Oklahoma, The	Hyaluronan synthase gene and uses thereof
CN101113436B (zh)	1997-10-31	2013-02-06	俄克拉何马大学董事会	透明质酸合酶基因及其应用
DE69841807D1 (de)	1997-11-06	2010-09-16	Novartis Vaccines & Diagnostic	Neisseriale antigene
US7192589B2 (en)	1998-09-16	2007-03-20	Genentech, Inc.	Treatment of inflammatory disorders with STIgMA immunoadhesins
PT1047784E (pt)	1998-01-14	2009-12-21	Novartis Vaccines & Diagnostic	Antigénios de neisseria meningitidis
CA2318029C (en)	1998-01-15	2009-05-19	Genentech, Inc.	Apo-2 ligand
US6727079B1 (en)	1998-02-25	2004-04-27	The United States Of America As Represented By The Department Of Health And Human Services	cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
NZ525914A (en)	1998-03-10	2004-03-26	Genentech Inc	Novel polypeptides and nucleic acids encoding the same
AU758353B2 (en)	1998-03-17	2003-03-20	Genentech Inc.	Polypeptides homologous to VEGF and BMP1
US6987023B2 (en)	1998-04-02	2006-01-17	The Board Of Regents Of The University Of Oklahoma	DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use
US7223571B2 (en)	1998-04-02	2007-05-29	The Board Of Regents Of The Universtiy Of Oklahoma	Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US20060188966A1 (en)	1998-04-02	2006-08-24	Deangelis Paul L	Natural, chimeric and hybrid glycosaminoglycan polymers and methods of making and using same
GB9808932D0 (en)	1998-04-27	1998-06-24	Chiron Spa	Polyepitope carrier protein
EP2261348A3 (en)	1998-05-01	2012-01-25	Novartis Vaccines and Diagnostics, Inc.	Neisseria meningitidis antigens and compositions
EP1076703B2 (en)	1998-05-15	2010-12-15	Genentech, Inc.	Therapeutic uses of il-17 homologous polypeptides
EP1865061A3 (en)	1998-05-15	2007-12-19	Genentech, Inc.	IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (en)	1998-05-15	2017-01-04	Genentech, Inc.	Il-17 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en)	2000-06-23	2002-11-21	Napoleone Ferrara	EG-VEGF nucleic acids and polypeptides and methods of use
AU756913B2 (en)	1998-08-21	2003-01-23	Immunex Corporation	Human IL-1 epsilon DNA and polypeptides
AU758062B2 (en)	1998-09-03	2003-03-13	Bristol-Myers Squibb Company	Enzymatic oxidative deamination process
WO2001051635A2 (en)	2000-01-13	2001-07-19	Genentech, Inc.	Novel stra6 polypeptides
JP2002527066A (ja)	1998-10-15	2002-08-27	カイロンコーポレイション	転移性乳癌および結腸癌調節遺伝子
US7094581B2 (en)	1998-10-26	2006-08-22	The Board Of Regents Of The University Of Oklahoma	Hyaluronan synthases and methods of making and using same
JP2003524389A (ja)	1998-12-16	2003-08-19	カイロンコーポレイション	ヒトサイクリン依存的キナーゼ（ｈＰＮＱＡＬＲＥ）
CA2450402A1 (en)	1998-12-22	2000-06-29	Genentech, Inc.	Methods and compositions for inhibiting cancer cell growth comprising pro224
EP1141299A2 (en)	1998-12-23	2001-10-10	Genentech, Inc.	Il-1 related polypeptides
WO2000066741A2 (en)	1999-04-30	2000-11-09	Chiron S.P.A.	Conserved neisserial antigens
GB9911683D0 (en)	1999-05-19	1999-07-21	Chiron Spa	Antigenic peptides
DE60043322D1 (de)	1999-06-15	2009-12-24	Genentech Inc	Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
US7101989B1 (en)	1999-07-09	2006-09-05	University Of North Carolina At Chapel Hill	DsrA protein and polynucleotides encoding the same
GB9916529D0 (en)	1999-07-14	1999-09-15	Chiron Spa	Antigenic peptides
JP2003527833A (ja)	1999-10-14	2003-09-24	クロンテック・ラボラトリーズ・インコーポレーテッド	花虫類に由来する発色団／蛍光体、およびそれらの使用法
IL148936A0 (en)	1999-10-20	2002-09-12	Genentech Inc	Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
JP2004508801A (ja)	1999-10-29	2004-03-25	カイロン　ソチエタ　ア　レスポンサビリタ　リミタータ	ナイセリア抗原性ペプチド
US7078382B1 (en)	1999-11-02	2006-07-18	Genentech, Inc.	Modulation of eNOS activity and therapeutic uses thereof
AU782918B2 (en)	1999-11-10	2005-09-08	University Of Washington	Compositions and methods for modulation of plant cell division
EP1669371A3 (en)	1999-12-01	2006-06-21	Genentech, Inc.	Composition and methods for the diagnosis of tumours
NZ520171A (en)	1999-12-20	2005-07-29	Immunex Corp	Tweak receptor
EP1897945B1 (en)	1999-12-23	2012-01-18	Genentech, Inc.	IL-17 homologous polypeptides and therapeutic uses thereof
AU7476600A (en)	1999-12-30	2001-07-16	Genencor International, Inc.	Trichoderma reesei xylanase
DE60134956D1 (de)	2000-01-10	2008-09-04	Novartis Vaccines & Diagnostic	Gene differentiell experimiert in brudtkrebs
US8273360B2 (en)	2000-01-17	2012-09-25	Novartis Ag	Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
US6992081B2 (en)	2000-03-23	2006-01-31	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
ATE343562T1 (de)	2000-03-23	2006-11-15	Elan Pharm Inc	Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
WO2004043361A2 (en)	2002-11-08	2004-05-27	Genentech, Inc.	Compositions and methods for the treatment of natural killer cell related diseases
CA2709771A1 (en)	2000-06-23	2002-01-03	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2792747A1 (en)	2000-06-23	2014-10-22	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
EP1299352B1 (en)	2000-06-30	2005-12-28	Elan Pharmaceuticals, Inc.	Compounds to treat alzheimer's disease
US6846813B2 (en)	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
EP2014298A3 (en)	2000-08-24	2009-10-07	Genentech, Inc.	Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1944317A3 (en)	2000-09-01	2008-09-17	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en)	2000-10-27	2004-01-06	Genentech, Inc.	Identification and modification of immunodominant epitopes in polypeptides
EP1671981A3 (en)	2000-10-27	2006-07-05	Chiron SRL.	Nucleic acids and proteins from streptococcus group A
GB0107661D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Staphylococcus aureus
GB0107658D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Streptococcus pneumoniae
WO2002081641A2 (en)	2001-04-06	2002-10-17	Georgetown University	Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en)	2001-04-06	2002-10-17	Georgetown University	Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en)	2001-04-06	2002-10-21	Georgetown University	Gene brcc-3 and diagnostic and therapeutic uses thereof
KR20080081201A (ko)	2001-04-16	2008-09-08	와이어쓰 홀딩스 코포레이션	폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
AU2002318371B2 (en)	2001-06-20	2006-06-15	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
BR0210721A (pt)	2001-06-27	2004-07-20	Elan Pharm Inc	Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
US6867189B2 (en)	2001-07-26	2005-03-15	Genset S.A.	Use of adipsin/complement factor D in the treatment of metabolic related disorders
EP1412381B1 (en)	2001-07-27	2010-06-02	Novartis Vaccines and Diagnostics S.r.l.	Antibodies against meningococcal adhesin app
MY144532A (en)	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
JP4361791B2 (ja)	2001-08-29	2009-11-11	ジェネンテック・インコーポレーテッド	マイトジェン活性を有するＢｖ８核酸及びポリペプチド
WO2003024392A2 (en)	2001-09-18	2003-03-27	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
EP1463520B1 (en)	2001-12-12	2008-09-03	Novartis Vaccines and Diagnostics S.r.l.	Immunisation against chlamydia trachomatis
EP1456223B1 (en)	2001-12-19	2009-08-12	The University Of Chicago	Rapidly maturing fluorescent proteins and methods for using the same
WO2003057160A2 (en)	2002-01-02	2003-07-17	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
EP2388265A1 (en)	2002-02-22	2011-11-23	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
US7138512B2 (en)	2002-04-10	2006-11-21	Georgetown University	Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en)	2002-04-10	2007-07-17	Georgetown University	Gene shinc-3 and diagnostic and therapeutic uses thereof
KR20040101502A (ko)	2002-04-16	2004-12-02	제넨테크, 인크.	종양의 진단 및 치료 방법 및 이를 위한 조성물
WO2003099848A2 (en)	2002-05-24	2003-12-04	Restoragen Inc.	Method for universal enzymatic production of bioactive peptides
WO2003099854A2 (en)	2002-05-24	2003-12-04	Nps Allelix Corp.	Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
EP2305710A3 (en)	2002-06-03	2013-05-29	Genentech, Inc.	Synthetic antibody phage libraries
US7700571B2 (en)	2002-06-05	2010-04-20	Genentech, Inc.	Compositions and methods for liver growth and liver protection
AU2003243400B2 (en)	2002-06-07	2009-10-29	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
EP2383278A1 (en)	2002-07-08	2011-11-02	Genentech, Inc.	Method to determine B cell mediated diseases
JP2006521082A (ja)	2002-09-11	2006-09-21	ジェネンテック・インコーポレーテッド	免疫関連疾患の治療のための新規組成物と方法
EP1539228B1 (en)	2002-09-11	2010-12-29	Genentech, Inc.	Novel composition and methods for the treatment of immune related diseases
EP2444409A2 (en)	2002-09-16	2012-04-25	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
EP2500438A3 (en)	2002-09-25	2012-11-28	Genentech, Inc.	Novel compositions and methods for the treatment of psoriasis
CN1703507B (zh)	2002-10-04	2010-09-29	弗门尼舍有限公司	倍半萜烯合成酶及其使用方法
EP2322203A3 (en)	2002-10-29	2011-07-27	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
DE60332477D1 (de)	2002-11-15	2010-06-17	Novartis Vaccines & Diagnostic	Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
CA2504144A1 (en)	2002-11-26	2004-06-10	Genentech, Inc.	Compositions and methods for the diagnosis of immune related diseases using pro7
AU2004219592C1 (en)	2003-03-12	2011-02-24	Genentech, Inc.	Use of Bv8 and/or EG-VEGF to promote hematopoiesis
DK2335725T3 (en)	2003-04-04	2017-01-23	Genentech Inc	Highly concentrated antibody and protein formulations
GB0308198D0 (en)	2003-04-09	2003-05-14	Chiron Srl	ADP-ribosylating bacterial toxin
AU2004235346A1 (en)	2003-04-25	2004-11-11	North Carolina State University	Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses therefore
EP2322540A1 (en)	2003-06-23	2011-05-18	North Carolina State University	Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof
PL1641822T3 (pl)	2003-07-08	2013-10-31	Genentech Inc	Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne
US7442785B2 (en)	2003-07-24	2008-10-28	The University Of Kentucky Research Foundation	Sesquiterpene synthase gene and protein
WO2005019258A2 (en)	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
ES2339710T5 (es)	2003-09-23	2017-10-05	University Of North Carolina At Chapel Hill	Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K
AU2004283246B2 (en)	2003-10-14	2009-07-23	Baxalta GmbH	Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives
DE602004024921D1 (de)	2003-11-17	2010-02-11	Genentech Inc	Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
ES2380765T3 (es)	2003-11-21	2012-05-18	Nps Pharmaceuticals, Inc.	Producción del péptido 2 de tipo glucagón y análogos
GB2426521A (en)	2004-02-02	2006-11-29	Ambrx Inc	Modified human four helical bundle polypeptides and their uses
US7459289B2 (en)	2004-03-08	2008-12-02	North Carolina State University	Lactobacillus acidophilus nucleic acid sequences encoding carbohydrate utilization-related proteins and uses therefor
KR20120126130A (ko)	2004-03-29	2012-11-20	가르파마 컴퍼니 리미티드	신규 갈렉틴 9 개변체 단백질 및 그 용도
US7250298B2 (en)	2004-04-07	2007-07-31	The University Of Chicago	Monomeric red fluorescent proteins
CN102532321B (zh)	2004-06-18	2018-10-12	Ambrx公司	新颖抗原结合多肽和其用途
CA2569381A1 (en)	2004-07-21	2006-08-31	Ambrx, Inc.	Biosynthetic polypeptides utilizing non-naturally encoded amino acids
KR20070068455A (ko)	2004-10-21	2007-06-29	와이어쓰	스타필로코커스 에피더미디스 폴리펩티드 항원의 면역원성조성물
CN101128586A (zh)	2004-12-22	2008-02-20	健泰科生物技术公司	制备可溶性多跨膜蛋白的方法
NZ555308A (en)	2004-12-22	2010-10-29	Ambrx Inc	Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US7939496B2 (en)	2004-12-22	2011-05-10	Ambrx, Inc.	Modified human growth horomone polypeptides and their uses
US20090325226A1 (en)	2005-03-15	2009-12-31	Stafford Darrel W	Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
EP1865940B1 (en)	2005-03-21	2013-02-13	Virobay, Inc.	Alpha ketoamide compounds as cysteine protease inhibitors
EP1871868A2 (en)	2005-04-15	2008-01-02	North Carolina State University	Methods and compositions to modulate adhesion and stress tolerance in bacteria
KR101242951B1 (ko)	2005-05-04	2013-03-13	질랜드 파마 에이/에스	글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
EP1891107B1 (en)	2005-05-12	2011-07-06	ZymoGenetics, Inc.	Compositions and methods for modulating immune responses
AU2006255686A1 (en)	2005-06-06	2006-12-14	Genentech, Inc.	Transgenic models for different genes and their use for gene characterization
CN101296613B (zh)	2005-07-29	2016-02-10	目标栽培公司	显性失活突变体krp蛋白保护活性细胞周期蛋白-cdk复合物不受野生型krp抑制
JP2009504183A (ja)	2005-08-15	2009-02-05	ジェネンテック・インコーポレーテッド	遺伝子破壊、それに関連する組成物および方法
WO2007027935A2 (en)	2005-08-31	2007-03-08	The Regents Of The University Of California	Cellular libraries of peptide sequences (clips) and methods of using the same
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
DE102005048898A1 (de)	2005-10-12	2007-04-19	Sanofi-Aventis Deutschland Gmbh	EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
IN2014DN06624A (pt)	2005-10-18	2015-07-10	Univ Colorado
WO2007053732A2 (en)	2005-11-01	2007-05-10	Mayo Foundation For Medical Education And Research	Promoter polymorphisms of the blys gene and use in diagnostic methods
WO2007059312A2 (en)	2005-11-16	2007-05-24	Ambrx, Inc.	Methods and compositions comprising non-natural amino acids
EP2002714A1 (en)	2005-11-21	2008-12-17	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
US8026354B2 (en)	2005-11-23	2011-09-27	Institut Pasteur	Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
RU2385877C1 (ru)	2005-12-22	2010-04-10	Дженентек, Инк.	Рекомбинантное получение связывающих гепарин белков
US20080311107A1 (en)	2006-02-17	2008-12-18	Genetech, Inc.	Novel Gene Disruptions, Compositions and Methods Relating Thereto
JP2009536022A (ja)	2006-04-19	2009-10-08	ジェネンテック・インコーポレーテッド	新規の遺伝子破壊、それに関連する組成物および方法
EP3026123A1 (en)	2006-04-27	2016-06-01	Klaritos, Inc.	Method and kit for predicting antibody therapy
WO2009030978A2 (en)	2006-06-09	2009-03-12	Novartis Ag	Conformers of bacterial adhesins
JP2009542225A (ja)	2006-06-30	2009-12-03	ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・ミシガン	組換え法によりｆｖｉｉｉタンパク質を生産する方法
EP2615108B1 (en)	2006-09-08	2016-10-26	Ambrx, Inc.	Modified human plasma polypeptide or fc scaffolds and thier uses
US7985783B2 (en)	2006-09-21	2011-07-26	The Regents Of The University Of California	Aldehyde tags, uses thereof in site-specific protein modification
EP2078040B1 (en)	2006-11-02	2017-06-28	Daniel J. Capon	Methods of producing hybrid polypeptides with moving parts
WO2008103962A2 (en)	2007-02-22	2008-08-28	Genentech, Inc.	Methods for detecting inflammatory bowel disease
KR20140012199A (ko)	2007-03-30	2014-01-29	암브룩스, 인코포레이티드	변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
MX2009011319A (es)	2007-04-20	2009-12-11	Enzon Pharmaceuticals Inc	Adenosina desaminasa recombinante estable.
EP2517714A1 (en)	2007-04-26	2012-10-31	Inspiration Biopharmaceuticals, Inc.	Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
CN111499748A (zh)	2007-07-16	2020-08-07	健泰科生物技术公司	抗cd79b抗体和免疫偶联物及使用方法
EP2641618A3 (en)	2007-07-16	2013-10-23	Genentech, Inc.	Humanized anti-CD79B antibodies and immunoconjugates and methods of use
WO2009014726A1 (en)	2007-07-26	2009-01-29	The Regents Of The University Of California	Methods for enhancing bacterial cell display of proteins and peptides
CN101361968B (zh)	2007-08-06	2011-08-03	健能隆医药技术（上海）有限公司	白介素-22在治疗脂肪肝中的应用
KR101662622B1 (ko)	2007-10-04	2016-10-05	지모제넥틱스, 인코포레이티드	Ｂ7 패밀리 구성원 ｚＢ7Ｈ6 및 관련된 조성물 및 방법
US20090233991A1 (en)	2007-11-01	2009-09-17	Hee Cheol Cho	Generation of biological pacemaker activity
WO2009059305A2 (en)	2007-11-01	2009-05-07	The University Of Chicago	Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
DK2217265T3 (en)	2007-11-20	2017-07-03	Ambrx Inc	Modified insulin polypeptides and their use
WO2009070648A2 (en)	2007-11-27	2009-06-04	Medtronic, Inc.	Humanized anti-amyloid beta antibodies
WO2009073511A2 (en)	2007-11-30	2009-06-11	Mayo Foundation For Medical Education And Research	Polymorphisms of the blys gene and use in diagnostic methods
HUE029869T2 (en)	2008-01-31	2017-04-28	Genentech Inc	Anti-cd79b antibodies and immunoconjugates and methods of use
CN103694337B (zh)	2008-02-08	2016-03-02	Ambrx公司	经修饰瘦素多肽和其用途
EP3263591B1 (en)	2008-02-21	2019-03-27	GlaxoSmithKline Biologicals S.A.	Meningococcal fhbp polypeptides
EP3605088A1 (en)	2008-04-09	2020-02-05	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
EA021131B1 (ru)	2008-05-16	2015-04-30	Тэйга Байотекнолоджис, Инк.	Антитела и способы их получения
WO2010011735A2 (en)	2008-07-23	2010-01-28	Ambrx, Inc.	Modified bovine g-csf polypeptides and their uses
DK3339321T3 (da)	2008-08-28	2021-06-21	Taiga Biotechnologies Inc	Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc
AU2009296267B2 (en)	2008-09-26	2013-10-31	Ambrx, Inc.	Non-natural amino acid replication-dependent microorganisms and vaccines
JP5694171B2 (ja)	2008-09-26	2015-04-01	アンブルックス, インコーポレイテッドAmbrx, Inc.	修飾されている動物のエリスロポエチンポリペプチドおよびそれらの使用
US9702877B2 (en)	2008-10-31	2017-07-11	Quest Diagnostics Investments Incorporated	BCR-ABL variants
JP2012509941A (ja)	2008-11-26	2012-04-26	ファイブ・プライム・セラピューティクス，インコーポレイテッド	Ｓｅｒｐｉｎｅ２によるコラーゲンおよび平滑筋アクチンの発現を調節するための組成物および方法
EA020843B1 (ru)	2009-02-03	2015-02-27	Амуникс Оперейтинг Инк.	Удлиненные рекомбинантные полипептиды и содержащие их композиции
TW201038286A (en)	2009-04-01	2010-11-01	Genentech Inc	Anti-FcRH5 antibodies and immunoconjugates and methods of use
EP2251025A1 (en)	2009-05-12	2010-11-17	Universitat Autònoma De Barcelona	Use of inclusion bodies as therapeutic agents
ITMI20090946A1 (it)	2009-05-28	2010-11-29	Novartis Ag	Espressione di proteine ricombinanti
WO2010144508A1 (en)	2009-06-08	2010-12-16	Amunix Operating Inc.	Glucose-regulating polypeptides and methods of making and using same
CN103140236B (zh)	2009-06-08	2017-04-19	阿穆尼克斯运营公司	生长激素多肽及其制备和使用方法
CN102711791A (zh)	2009-07-03	2012-10-03	比奥诺尔免疫有限公司	用于hiv疫苗组合物或作为诊断方法的hiv相关肽的组合或融合物
JP2013502458A (ja)	2009-08-24	2013-01-24	アムニクスオペレーティングインコーポレイテッド	凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
ES2562259T3 (es)	2009-08-27	2016-03-03	Glaxosmithkline Biologicals Sa	Polipéptidos híbridos que incluyen secuencias fHBP meningocócicas
US9488656B2 (en)	2009-09-30	2016-11-08	Quest Diagnostics Investments Incorporated	BCR-ABL truncation mutations
US20120219952A1 (en)	2009-10-06	2012-08-30	Patrice Nordmann	Carbapenemase and antibacterial treatment
WO2011047267A1 (en)	2009-10-15	2011-04-21	Genentech, Inc.	Chimeric fibroblast growth factors with altered receptor specificity
RU2539772C2 (ru)	2009-10-22	2015-01-27	Дженентек, Инк.	Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
AU2010310985B2 (en)	2009-10-27	2014-11-06	Glaxosmithkline Biologicals S.A.	Modified meningococcal fHBP polypeptides
AR078986A1 (es)	2009-11-12	2011-12-14	Genentech Inc	Un metodo para promover la densidad de espinas dendriticas
JP5856065B2 (ja)	2009-11-30	2016-02-09	ジェネンテック，インコーポレイテッド	腫瘍の診断と治療のための組成物と方法
JP2013515080A (ja)	2009-12-21	2013-05-02	アンブルックス，インコーポレイテッド	修飾されているウシのソマトトロピンポリペプチドおよびそれらの使用
EA201290542A1 (ru)	2009-12-21	2013-07-30	Амбркс, Инк.	Модифицированные свиные соматотропиновые полипептиды и их применение
FR2954349A1 (fr)	2009-12-22	2011-06-24	Agronomique Inst Nat Rech	Sulfatase modifiant selectivement les glycosaminoglycanes
BR112012020373A8 (pt)	2010-02-23	2018-01-02	Genentech Inc	anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
WO2011123813A2 (en)	2010-04-02	2011-10-06	Amunix Operating Inc.	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
SG185027A1 (en)	2010-05-03	2012-11-29	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
CN103221420A (zh)	2010-05-19	2013-07-24	北卡罗莱纳州立大学	用于递送治疗性肽的组合物和方法
WO2011149461A1 (en)	2010-05-27	2011-12-01	Medtronic, Inc.	Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US20130150286A1 (en)	2010-06-25	2013-06-13	Jean-Claude Sirard	Methods and pharmaceutical compositions for the treatment of respiratory tract infections
CN103221422B (zh)	2010-07-29	2017-03-29	十一生物治疗股份有限公司	嵌合il‑1受体i型激动剂和拮抗剂
ES2972902T3 (es)	2010-08-17	2024-06-17	Ambrx Inc	Polipéptidos de relaxina modificados y sus usos
US9567386B2 (en)	2010-08-17	2017-02-14	Ambrx, Inc.	Therapeutic uses of modified relaxin polypeptides
EP2420253A1 (en)	2010-08-20	2012-02-22	Leadartis, S.L.	Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
US8729233B2 (en)	2010-08-30	2014-05-20	Board Of Trustees Of Michigan State University	Microbial nanowires and products related thereto
CN102380091A (zh)	2010-08-31	2012-03-21	健能隆医药技术（上海）有限公司	白介素-22在治疗病毒性肝炎中的应用
CN103797026A (zh)	2010-09-15	2014-05-14	阿利吉那科技有限公司	由木质素衍生的化合物生物生产芳香族化学品
TWI480288B (zh)	2010-09-23	2015-04-11	Lilly Co Eli	牛顆粒細胞群落刺激因子及其變體之調配物
US20150139991A1 (en)	2010-10-15	2015-05-21	Leadartis, S.L.	Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain
EP2441776A1 (en)	2010-10-15	2012-04-18	Leadartis, S.L.	Generation of multifunctional and multivalent polypeptide complexes with collagen XVIII trimerization domain
WO2012088222A2 (en)	2010-12-21	2012-06-28	The University Of North Carolina At Chapel Hill	Methods and compositions for producing active vitamin k-dependent proteins
US8603740B2 (en)	2010-12-29	2013-12-10	Quest Diagnostics Investments Incorporated	BCR-ABL1 splice variants and uses thereof
WO2012095684A1 (en)	2011-01-10	2012-07-19	Inserm ( Institut National De La Sante Et De La Recherche Medicale)	Methods for the screening of substances useful for the prevention and treatment of neisseria infections
WO2012103240A2 (en)	2011-01-25	2012-08-02	Eleven Biotherapeutics, Inc.	Receptor binding agents
MX343729B (es)	2011-04-08	2016-11-18	Amgen Inc	Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos.
WO2013011072A1 (en)	2011-07-20	2013-01-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Carbapenemase and antibacterial treatment
CN104066439A (zh)	2011-07-29	2014-09-24	十一生物治疗股份有限公司	纯化的蛋白质
WO2013033456A2 (en)	2011-09-02	2013-03-07	Board Of Trustees Of Michigan State University	Microbial nanowires and methods of making and using
BR112014018575A2 (pt)	2012-01-26	2017-07-04	Amgen Inc	polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
EP3549953A1 (en)	2012-02-15	2019-10-09	Bioverativ Therapeutics Inc.	Recombinant factor viii proteins
KR102097263B1 (ko)	2012-02-15	2020-04-06	바이오버라티브 테라퓨틱스 인크.	Viii 인자 조성물 및 이를 제조하고 사용하는 방법
CN107496932A (zh)	2012-02-27	2017-12-22	阿穆尼克斯运营公司	Xten缀合组合物和制造其的方法
SG10202007206WA (en)	2012-03-27	2020-08-28	Genentech Inc	Improved harvest operations for recombinant proteins
WO2013163606A1 (en)	2012-04-27	2013-10-31	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Vascular endothelial growth factor antagonists and methods for their use
BR112014027345A2 (pt)	2012-05-03	2019-09-03	Zealand Pharma As	análogos de peptídeo 2 semelhante ao glucagon (glp-2)
WO2013182660A1 (en)	2012-06-06	2013-12-12	Bionor Immuno As	Hiv vaccine
DK2877189T3 (da)	2012-07-20	2021-02-22	Taiga Biotechnologies Inc	Forbedret rekonstituering og autorekonstituering af det hæmopoietiske kammer
US9309510B2 (en)	2012-08-10	2016-04-12	Cytomx Therapeutics, Inc.	Protease-resistant systems for polypeptide display and methods of making and using thereof
AU2013348029A1 (en)	2012-11-20	2015-07-02	The University Of North Carolina At Chapel Hill	Methods and compositions for modified factor IX proteins
WO2014088934A1 (en)	2012-12-07	2014-06-12	Danisco Us Inc.	Compositions and methods of use
WO2014088940A1 (en)	2012-12-07	2014-06-12	Danisco Us Inc.	Compositions and methods of use
US10272115B2 (en)	2013-03-11	2019-04-30	Taiga Biotechnologies, Inc.	Production and use of red blood cells
SG11201507447PA (en)	2013-03-13	2015-10-29	Eleven Biotherapeutics Inc	Chimeric cytokine formulations for ocular delivery
PT3611180T (pt)	2013-03-15	2022-03-15	Biomolecular Holdings Llc	Imunoglobulina híbrida que contém uma ligação não peptídica
EP2970422B1 (en)	2013-03-15	2018-04-18	F.Hoffmann-La Roche Ag	Il-22 polypeptides and il-22 fc fusion proteins and methods of use
WO2015007337A1 (en)	2013-07-19	2015-01-22	Bionor Immuno As	Method for the vaccination against hiv
US10548953B2 (en)	2013-08-14	2020-02-04	Bioverativ Therapeutics Inc.	Factor VIII-XTEN fusions and uses thereof
WO2015059690A1 (en)	2013-10-24	2015-04-30	Yeda Research And Development Co. Ltd.	Polynucleotides encoding brex system polypeptides and methods of using s ame
EP3062889A2 (en)	2013-11-01	2016-09-07	Spherium Biomed S.L.	Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
CN104623637A (zh)	2013-11-07	2015-05-20	健能隆医药技术（上海）有限公司	Il-22二聚体在制备静脉注射药物中的应用
WO2015116902A1 (en)	2014-01-31	2015-08-06	Genentech, Inc.	G-protein coupled receptors in hedgehog signaling
EP3116486B1 (en)	2014-03-14	2019-12-04	Daniel J. Capon	Hybrid immunoglobulin containing non-peptidyl linkage
WO2016005508A1 (en)	2014-07-11	2016-01-14	Bionor Immuno As	Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
US20170211054A1 (en)	2014-09-30	2017-07-27	Dansico Us Inc.	Compositions comprising beta mannanase and methods of use
WO2016054185A1 (en)	2014-09-30	2016-04-07	Danisco Us Inc	Compositions comprising beta-mannanase and methods of use
WO2016054176A1 (en)	2014-09-30	2016-04-07	Danisco Us Inc	Compositions comprising beta-mannanase and methods of use
EP3201334A1 (en)	2014-09-30	2017-08-09	Danisco US Inc.	Compositions comprising beta-mannanase and methods of use
US20170211053A1 (en)	2014-09-30	2017-07-27	Danisco Us Inc.	Compositions comprising beta mannanase and methods of use
MX2017004947A (es)	2014-10-24	2017-06-29	Bristol Myers Squibb Co	Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
WO2016100837A1 (en)	2014-12-18	2016-06-23	Danisco Us Inc	Engineered multifunctional enzymes and methods of use
US20180002683A1 (en)	2014-12-18	2018-01-04	Danisco Us Inc.	Engineered multifunctional enzymes and methods of use
EP3253786A4 (en)	2015-02-06	2018-10-17	The University of North Carolina at Chapel Hill	Optimized human clotting factor viii gene expression cassettes and their use
ES2752054T3 (es)	2015-03-31	2020-04-02	Novimmune Sa	Método para optimizar el ensamble y producción de complejos de proteínas heteromultiméricas
JP2018515603A (ja)	2015-05-04	2018-06-14	ビオノル・イムノ・アクシェセルスカプＢｉｏｎｏｒＩｍｍｕｎｏＡＳ	Ｈｉｖワクチン用の投薬レジメン
MX2018001497A (es)	2015-08-03	2018-05-15	Bioverativ Therapeutics Inc	Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
US11713358B2 (en)	2015-08-28	2023-08-01	Amunix Pharmaceuticals, Inc.	Chimeric polypeptide assembly and methods of making and using the same
JP2019510517A (ja)	2016-03-29	2019-04-18	ジェルター，インコーポレイテッド	細胞質内体積に対するペリプラズム体積の比率が０．５：１および１０：１の間にあるグラム陰性細菌におけるタンパク質の発現
ES2930351T3 (es)	2016-04-15	2022-12-09	Evive Biotechnology Shanghai Ltd	Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
US10590426B2 (en)	2016-08-22	2020-03-17	Board Of Trustees Of Michigan State University	Genetic control of cell size
US10583156B2 (en)	2016-12-02	2020-03-10	Taiga Biotechnologies, Inc.	Nanoparticle formulations
CN110267663A (zh)	2016-12-06	2019-09-20	卡莱多生物科技有限公司	聚糖聚合物及其相关方法
IL250479A0 (en)	2017-02-06	2017-03-30	Sorek Rotem	Genetically engineered cells expressing a disarm system that confers resistance to phages and methods for their production
ES2963839T3 (es)	2017-02-08	2024-04-02	Bristol Myers Squibb Co	Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
WO2018152496A1 (en)	2017-02-17	2018-08-23	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Compositions and methods for the diagnosis and treatment of zika virus infection
SG11202000612TA (en)	2017-08-03	2020-02-27	Taiga Biotechnologies Inc	Methods and compositions for the treatment of melanoma
US10149898B2 (en)	2017-08-03	2018-12-11	Taiga Biotechnologies, Inc.	Methods and compositions for the treatment of melanoma
US11180541B2 (en)	2017-09-28	2021-11-23	Geltor, Inc.	Recombinant collagen and elastin molecules and uses thereof
EP3743088B1 (en)	2018-01-26	2022-10-12	F. Hoffmann-La Roche AG	Il-22 fc compositions and methods of use
SG11202006259SA (en)	2018-01-26	2020-08-28	Genentech Inc	Il-22 fc fusion proteins and methods of use
JP2021514354A (ja)	2018-02-21	2021-06-10	ジェネンテック，インコーポレイテッド	ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与
IL258467A (en)	2018-03-29	2018-07-04	Ilana Kolodkin Gal	Methods of disrupting a biofilm and/or preventing formation of same
SG11202009884YA (en)	2018-04-09	2020-11-27	Amgen Inc	Growth differentiation factor 15 fusion proteins
MX2020012397A (es)	2018-05-18	2021-04-12	Bioverativ Therapeutics Inc	Metodos de tratamiento de la hemofilia a.
JP7557377B2 (ja)	2018-06-06	2024-09-27	レアダルティス、ソシエダッドリミターダ	三量体ポリペプチド複合体およびその使用
US12049485B2 (en)	2018-09-11	2024-07-30	Ambrx, Inc.	Interleukin-2 polypeptide conjugates and their uses
WO2020202142A2 (en)	2019-03-31	2020-10-08	Yeda Research And Development Co. Ltd.	Anti-viral and anti-tumoral compounds
WO2020210231A1 (en)	2019-04-08	2020-10-15	Taiga Biotechnologies, Inc.	Compositions and methods for the cry opreservation of immune cells
US11168126B2 (en)	2019-04-12	2021-11-09	Geltor, Inc.	Recombinant elastin and production thereof
KR102134418B1 (ko) *	2019-06-17	2020-07-16	씨제이제일제당 주식회사	L-타이로신을 생산하는 미생물 및 이를 이용한 l-타이로신 생산 방법
CA3174114A1 (en)	2020-03-11	2021-09-16	Ambrx, Inc.	Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021207662A1 (en)	2020-04-10	2021-10-14	Genentech, Inc.	Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
IL288680A (en)	2021-12-05	2023-07-01	Yeda Res & Dev	Genetically modified phages and their use
WO2024133316A1 (en)	2022-12-23	2024-06-27	Thermo Fisher Scientific Baltics Uab	Closed system for expressing recombinant proteins using e. coli and methods for producing clarified cell cultures thereof
WO2024175778A2 (en)	2023-02-23	2024-08-29	Micropep Technologies S.A.	Antifungal peptides to control plant pathogens

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4237224A (en) *	1974-11-04	1980-12-02	Board Of Trustees Of The Leland Stanford Jr. University	Process for producing biologically functional molecular chimeras
EP0001929B1 (en) *	1977-11-08	1989-04-19	Genentech, Inc.	Plasmid for transforming bacterial host to render it capable of polypeptide expression
US4366246A (en) *	1977-11-08	1982-12-28	Genentech, Inc.	Method for microbial polypeptide expression
FI793884A (fi) *	1978-12-26	1980-06-27	Cetus Corp	Stabila plasmider med stort kopieantal
US4631257A (en)	1978-12-26	1986-12-23	Cetus Corporation	Stable high copy number plasmids
US4332892A (en)	1979-01-15	1982-06-01	President And Fellows Of Harvard College	Protein synthesis
AU542264B2 (en) *	1979-06-01	1985-02-14	G.D. Searle & Co.	Plasmid vectors
US4342832A (en) *	1979-07-05	1982-08-03	Genentech, Inc.	Method of constructing a replicable cloning vehicle having quasi-synthetic genes
GB2068970B (en) *	1980-02-06	1983-06-22	Searle & Co	Recombinant dna technique for the preparation of a protein resembling human interferon
DK33181A (da) *	1980-02-06	1981-08-07	Searle & Co	Fremgangsmaade til fremstilling af et interferonlignende protein
CH657141A5 (de) *	1980-07-01	1986-08-15	Hoffmann La Roche	Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
IT1139487B (it) *	1980-09-25	1986-09-24	Genentech Inc	Produzione microbica di interferone di fibroblasti umani
JPS5780398A (en) *	1980-11-05	1982-05-19	Sanraku Inc	Plasmid produced by genetic manipulation, coliform bacillus having the same and preparation of tryptophan with said bacillus
DK489481A (da) *	1980-11-10	1982-05-11	Searle & Co	Plasmidvektor og frmgangsmaade til fremstilling deraf
US5145782A (en) *	1980-12-08	1992-09-08	The Regents Of The University Of California	DNA expression vector suitable for direct expression of a foreign gene
IE52417B1 (en) *	1980-12-12	1987-10-28	Unilever Plc	Dna sequences encoding various allelic forms of mature thaumatin,recombinant plasmids comprising said dnas and a process for their preparation,bacterial cultures comprising said recombinant plasmids,and method for producing mature thaumatin

1981
- 1981-03-02 ZA ZA00811368A patent/ZA811368B/xx unknown
- 1981-03-03 BG BG078443A patent/BG46005A3/xx unknown
- 1981-03-13 ZW ZW54/81A patent/ZW5481A1/xx unknown
- 1981-03-20 GR GR64454A patent/GR74818B/el unknown
- 1981-03-20 CA CA000373565A patent/CA1198068A/en not_active Expired
- 1981-03-20 FI FI810876A patent/FI810876L/fi not_active Application Discontinuation
- 1981-03-23 PT PT72716A patent/PT72716B/pt unknown
- 1981-03-23 NZ NZ207660A patent/NZ207660A/en unknown
- 1981-03-23 YU YU756/81A patent/YU45534B/xx unknown
- 1981-03-23 DK DK198101299A patent/DK173085B1/da active
- 1981-03-23 ES ES500617A patent/ES8207220A1/es not_active Expired
- 1981-03-23 DE DE3153606A patent/DE3153606C2/de not_active Expired - Lifetime
- 1981-03-23 GB GB8108986A patent/GB2073203B/en not_active Expired
- 1981-03-23 NZ NZ196584A patent/NZ196584A/en unknown
- 1981-03-23 BR BR8101712A patent/BR8101712A/pt not_active IP Right Cessation
- 1981-03-23 AT AT85100548T patent/ATE52802T1/de not_active IP Right Cessation
- 1981-03-23 IL IL62460A patent/IL62460A/xx not_active IP Right Cessation
- 1981-03-23 AT AT83200301T patent/ATE27306T1/de not_active IP Right Cessation
- 1981-03-23 AT AT81301227T patent/ATE34183T1/de active
- 1981-03-23 JP JP56040529A patent/JPH0724582B2/ja not_active Expired - Lifetime
- 1981-03-23 DD DD81243409A patent/DD204494A5/de unknown
- 1981-03-23 FR FR8105732A patent/FR2480781B1/fr not_active Expired
- 1981-03-23 DD DD81228534A patent/DD159435A5/de unknown
- 1981-03-23 BG BG078444A patent/BG45220A3/xx unknown
- 1981-03-23 OA OA57360A patent/OA06774A/xx unknown
- 1981-03-23 EP EP85100548A patent/EP0154133B1/en not_active Expired - Lifetime
- 1981-03-23 CS CS816230A patent/CS238645B2/cs unknown
- 1981-03-23 BG BG051341A patent/BG42526A3/xx unknown
- 1981-03-23 AU AU68636/81A patent/AU542640B2/en not_active Expired
- 1981-03-23 DE DE8383200301T patent/DE3176205D1/de not_active Expired
- 1981-03-23 DD DD81243408A patent/DD203746A5/de unknown
- 1981-03-23 KR KR1019810000949A patent/KR830005351A/ko unknown
- 1981-03-23 CS CS812106A patent/CS238612B2/cs unknown
- 1981-03-23 DE DE19813111405 patent/DE3111405A1/de active Granted
- 1981-03-23 NO NO810986A patent/NO810986L/no unknown
- 1981-03-23 PH PH25398A patent/PH17537A/en unknown
- 1981-03-23 IT IT67406/81A patent/IT1144324B/it active
- 1981-03-23 EP EP81301227A patent/EP0036776B1/en not_active Expired
- 1981-03-23 IL IL71885A patent/IL71885A/xx not_active IP Right Cessation
- 1981-03-23 DE DE8181301227T patent/DE3176737D1/de not_active Expired
- 1981-03-23 HU HU81732A patent/HU195534B/hu unknown
- 1981-03-23 AR AR81284705A patent/AR248050A1/es active
- 1981-03-23 IE IE656/86A patent/IE51893B1/en not_active IP Right Cessation
- 1981-03-23 EP EP83200301A patent/EP0086548B1/en not_active Expired
- 1981-03-23 IE IE657/86A patent/IE51894B1/en not_active IP Right Cessation
- 1981-03-23 NZ NZ207659A patent/NZ207659A/en unknown
- 1981-03-23 IE IE636/81A patent/IE51892B1/en not_active IP Right Cessation
- 1981-03-23 DE DE8585100548T patent/DE3177179D1/de not_active Expired - Lifetime
- 1981-03-23 CS CS816231A patent/CS238646B2/cs unknown
- 1981-03-24 MX MX81101935U patent/MX7689E/es unknown
- 1981-03-24 PL PL1981252630A patent/PL147727B1/pl unknown
- 1981-03-24 DZ DZ816135A patent/DZ278A1/fr active
- 1981-03-24 PL PL81230296A patent/PL162227B1/pl unknown
1982
- 1982-02-26 ES ES509935A patent/ES509935A0/es active Granted
- 1982-02-26 ES ES509936A patent/ES8305042A1/es not_active Expired
- 1982-11-12 PH PH28133A patent/PH18915A/en unknown
- 1982-11-12 PH PH28134A patent/PH20110A/en unknown
- 1982-11-12 PH PH28135A patent/PH20736A/en unknown
1984
- 1984-02-14 YU YU00260/84A patent/YU26084A/xx unknown
- 1984-05-21 IL IL71885A patent/IL71885A0/xx unknown
- 1984-06-27 AU AU29964/84A patent/AU580959B2/en not_active Expired
- 1984-06-27 AU AU29963/84A patent/AU585832B2/en not_active Expired
- 1984-09-18 NO NO84843719A patent/NO165644C/no not_active IP Right Cessation
- 1984-09-18 NO NO84843718A patent/NO161572C/no not_active IP Right Cessation
- 1984-12-19 FR FR8419450A patent/FR2555199B1/fr not_active Expired
1985
- 1985-05-21 CA CA000482003A patent/CA1213539A/en not_active Expired
- 1985-09-12 FI FI853489A patent/FI72344C/fi not_active IP Right Cessation
- 1985-09-12 FI FI853488A patent/FI853488L/fi not_active Application Discontinuation
- 1985-12-30 MY MY896/85A patent/MY8500896A/xx unknown
1986
- 1986-03-29 KR KR1019860002404A patent/KR860001230B1/ko not_active IP Right Cessation
1992
- 1992-10-13 JP JP4274165A patent/JPH0673469B2/ja not_active Expired - Lifetime
- 1992-10-13 JP JP4274172A patent/JPH0734747B2/ja not_active Expired - Lifetime
1993
- 1993-04-29 US US08/055,960 patent/US5888808A/en not_active Expired - Lifetime
1995
- 1995-06-06 US US08/482,321 patent/US6333174B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
IE51893B1 (en)	1987-04-29
FI853488A0 (fi)	1985-09-12
HU195534B (en)	1988-05-30
PH18915A (en)	1985-11-06
ATE52802T1 (de)	1990-06-15
AU6863681A (en)	1981-10-01
EP0086548A3 (en)	1983-11-30
PH17537A (en)	1984-09-19
AU2996484A (en)	1984-10-18
MY8500896A (en)	1985-12-31
PT72716A (en)	1981-04-01
CS238645B2 (en)	1985-12-16
IE860657L (en)	1981-09-24
NO843719L (no)	1981-09-25
YU45534B (en)	1992-05-28
JPH05268962A (ja)	1993-10-19
JPH0734747B2 (ja)	1995-04-19
JPH0724582B2 (ja)	1995-03-22
PL230296A1 (pt)	1982-01-18
PH20110A (en)	1986-09-29
IL71885A0 (en)	1984-09-30
OA06774A (fr)	1982-06-30
DE3176205D1 (en)	1987-06-25
JPH05211885A (ja)	1993-08-24
ES8304206A1 (es)	1983-03-16
ATE34183T1 (de)	1988-05-15
CA1198068A (en)	1985-12-17
PT72716B (en)	1982-03-19
DD203746A5 (de)	1983-11-02
FI72344C (fi)	1987-05-11
IE51894B1 (en)	1987-04-29
DE3177179D1 (de)	1990-06-21
BG46005A3 (en)	1989-09-15
AU542640B2 (en)	1985-02-28
DE3111405A1 (de)	1982-03-25
FR2480781B1 (fr)	1985-10-18
ZW5481A1 (en)	1981-10-21
DK129981A (da)	1981-09-25
IE810656L (en)	1981-09-25
FI853488L (fi)	1985-09-12
YU26084A (en)	1989-02-28
CA1213539A (en)	1986-11-04
YU75681A (en)	1985-03-20
DE3111405C2 (pt)	1990-06-21
AU585832B2 (en)	1989-06-29
KR830005351A (ko)	1983-08-13
ES509936A0 (es)	1983-04-01
NO161572C (no)	1989-08-30
US6333174B1 (en)	2001-12-25
DZ278A1 (fr)	2004-09-13
ES8305042A1 (es)	1983-04-01
NZ207659A (en)	1985-12-13
ZA811368B (en)	1982-04-28
AU2996384A (en)	1984-10-18
IT8167406A0 (it)	1981-03-23
PH20736A (en)	1987-04-02
BG42526A3 (en)	1987-12-15
JPH0673469B2 (ja)	1994-09-21
FI810876L (fi)	1981-09-25
EP0154133B1 (en)	1990-05-16
CS238612B2 (en)	1985-12-16
JPS56145221A (en)	1981-11-11
IT1144324B (it)	1986-10-29
ES500617A0 (es)	1982-09-16
DK173085B1 (da)	1999-12-27
NO165644B (no)	1990-12-03
BR8101712A (pt)	1981-09-29
NZ207660A (en)	1985-12-13
EP0036776A2 (en)	1981-09-30
EP0036776A3 (en)	1982-10-27
NO843718L (no)	1981-09-25
AU580959B2 (en)	1989-02-09
AR248050A1 (es)	1995-05-31
GB2073203A (en)	1981-10-14
ES8207220A1 (es)	1982-09-16
NO165644C (no)	1991-03-13
NZ196584A (en)	1985-12-13
FI853489L (fi)	1985-09-12
BG45220A3 (bg)	1989-04-14
IL62460A0 (en)	1981-05-20
PL162227B1 (pl)	1993-09-30
EP0154133A3 (en)	1986-05-28
GR74818B (pt)	1984-07-12
DE3153606C2 (pt)	1991-04-25
FR2555199A1 (fr)	1985-05-24
US5888808A (en)	1999-03-30
NO810986L (no)	1981-09-25
IL71885A (en)	1986-01-31
ES509935A0 (es)	1983-03-16
IE51892B1 (en)	1987-04-29
DE3176737D1 (en)	1988-06-16
PL147727B1 (en)	1989-07-31
FR2555199B1 (fr)	1987-09-04
FI72344B (fi)	1987-01-30
FR2480781A1 (fr)	1981-10-23
ATE27306T1 (de)	1987-06-15
DD159435A5 (de)	1983-03-09
EP0086548A2 (en)	1983-08-24
EP0154133A2 (en)	1985-09-11
NO161572B (no)	1989-05-22
CS238646B2 (en)	1985-12-16
KR860001230B1 (ko)	1986-08-30
GB2073203B (en)	1984-02-29
MX7689E (es)	1990-08-14
IL62460A (en)	1986-01-31
EP0086548B1 (en)	1987-05-20
EP0036776B1 (en)	1988-05-11
FI853489A0 (fi)	1985-09-12
IE810636L (en)	1981-09-24

Publication	Publication Date	Title
DD204494A5 (de)	1983-11-30	Verfahren zum schneiden doppelstraengiger dns
DE3280422T2 (de)	1993-05-27	Verfahren und produkte zur leichten mikrobiologischen expression von dns-sequenzen.
DE3050725C2 (pt)	1988-03-10
DE3486216T2 (de)	1994-02-17	Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.
DE3043981C2 (pt)	1989-11-30
DE3177288T2 (de)	1992-12-10	Reife menschliche leukozyten-interferone, verfahren zu ihrer bacteriellen herstellung, zwischenprodukte hierfuer und zusammensetzungen diese enthaltend.
DE69629576T2 (de)	2004-06-24	Verfahren zur herstellung von rekombinanten plasmiden
CH663032A5 (de)	1987-11-13	Doppelstraengige dna, replizierbare plasmidische expressionstraeger zur mikrobiellen herstellung von hybrid human-leukozyten-interferon und transformierte mikroorganismen.
DD203330A5 (de)	1983-10-19	Verfahren zur herstellung hybrider human-leukozyten-interferone
LU83648A1 (de)	1983-06-08	Human-fibroblasten-interferon und dessen herstellung
DD154022A5 (de)	1982-02-17	Verfahren zur herstellung von menschlichem pre-wachstumshormon
DE2858357C2 (pt)	1990-03-15
DD212982A5 (de)	1984-08-29	Verfahren zur herstellung von rinder-wachstumshormon-aehnlichen polypeptiden
DE2848052A1 (de)	1979-05-10	Synthetische dna und verfahren zu ihrer herstellung
DD212532A5 (de)	1984-08-15	Verfahren zur stabilisierung und selektion von wirtszellen, die rekombinierende dna enthalten
DD201693A5 (de)	1983-08-03	Verfahren zur synthetisierung von menschlichem proinsulin
DE3688870T2 (de)	1993-12-23	Dns-sequenz.
DE69303685T2 (de)	1997-01-02	Verfahren zur Expression von Rezeptoren des menschlichen Nervensystems in der Hefe Schizosaccharomyces Pombe
AT386609B (de)	1988-09-26	Verfahren zum herstellen eines mikroorganismus
AT386607B (de)	1988-09-26	Verfahren zum herstellen eines dns-transfer-vektors
DE69122545T2 (de)	1997-04-24	Verfahren zur Herstellung von menschlichem Nervenwachstumsfaktor durch Genmanipulation
AT394210B (de)	1992-02-25	Verfahren zur herstellung von doppelstraengiger dna kodierend fuer hybride human-leukozyten-interferone
AT389890B (de)	1990-02-12	Verfahren zur herstellung von humaninsulin
DE3514113A1 (de)	1986-10-23	Veraenderung der dna-sequenz zwischen shine-dalgarno-sequenz und startcodon des trp-operons zur steigerung der proteinexpression
DD298269A5 (de)	1992-02-13	Verfahren zur herstellung von fremdproteinen in tierischen zellen